By Josh White
Date: Wednesday 22 Oct 2025
(Sharecast News) - Novacyt said on Wednesday that it expects improved second-half performance in 2025, as it outlined a new growth strategy focused on accelerating product development, achieving sustained double-digit revenue growth, and returning to EBITDA profitability.
The AIM-traded, Paris- and Manchester-based molecular diagnostics group said revenue in the second half...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news